Diamyd® is currently being evaluated in the first-ever precision medicine Phase III trial www.DIAGNODE-3.com in individuals recently diagnosed with Type 1 Diabetes carrying the HLA DR3-DQ2 genotype.

We are very pleased with the @fda.gov decision to grant Fast Track designation for #Diamyd and the potential this provides to accelerate Diamyd’s path to entering the US market", says Ulf Hannelius, CEO of Diamyd Medical. 💙